RegenLab manufactures and sells sterile, single-use kits that enable physicians to prepare autologous platelet-rich plasma (PRP) at the point of care. The company operates a consumable business model, generating revenue from disposable kits used in musculoskeletal, wound care, and aesthetic procedures. RegenLab's core product offerings include RegenKit PRP, a preparation system for orthopedic and dermatological applications, and Cellular Matrix, a proprietary kit combining PRP with hyaluronic acid in a single tube to treat knee osteoarthritis and skin conditions. The company also offers RegenKit Wound Gel for chronic wounds such as diabetic foot ulcers. RegenLab manufactures its kits in cleanroom facilities located in the United States, France, and Switzerland. The company sells its products through a combination of direct sales teams in key European and North American markets and distribution partners in over 90 countries, including Stryker and MiMedx. RegenLab's strategy centers on expanding its U.S. wound care presence, securing U.S. regulatory approval for Cellular Matrix, and commercializing next-generation therapies for advanced joint disease.